A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)

• Status: Completed
• Trial end date: 2022-01-25
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of QL1207 compared to Eylea® in subjects with wet AMD.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qilu Pharmaceutical Co., Ltd.
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

1. Age ≥ 50 years male and female

2. Treatment naïve, *active subfoveal choroidal neovascularisation (CNV) lesion secondary to AMD in the study eye

3. CNV area ≥50% of total lesion size

4. Total lesion area ≤ 12.0 Disc Areas (DA) in size (including blood, scars, and neovascularisation) in the study eye

5. BCVA of 20/40 to 20/200 (letter score of 73 to 34, inclusive) using ETDRS charts in the study eye

6. Fellow eye is not expected to need any anti-VEGF treatment for the duration of study participation.

Exclusion Criteria:

Study eye:

1. Sub- or intra-retinal haemorrhage that comprises more than 50% of the entire lesion or presence of blood with the size of 1 DA or more involving the centre of fovea

2. Scar, fibrosis, or atrophy involving the centre of the fovea

3. Presence of CNV due to other causes, such as ocular histoplasmosis, trauma, multifocal choroiditis, angioid streaks, history of choroidal rupture, or pathologic myopia

4. Any concurrent macular abnormality other than AMD which could affect central vision or the efficacy of IP

5. Current vitreous haemorrhage within 30days before randomization

6. Any other intraocular surgery or periocular surgery within 90 days prior to randomisation, except for lid surgery, which may not have taken place within 30 days prior to randomisation.

7. Uncontrolled ocular hypertension (defined as intraocular pressure [IOP] ≥ 25 mmHg despite treatment with anti-glaucoma medication) at Screening

Either eye:

8. Any previous IVT anti-vascular endothelial growth factor (VEGF) treatment

9. Any previous systemic anti-VEGF treatment

10. History of treatment involving macula such as macular laser photocoagulation, photodynamic therapy (PDT), transpupillary thermotherapy (TTT), radiation therapy, or any ocular treatment for neovascular AMD

11. Active or suspected ocular and periocular infection at Screening or at randomisation

12. History of idiopathic or autoimmune-associated uveitis

Other:

13. Known allergic reactions and/or hypersensitivity to any component of Eylea or QL1207 or allergy to the fluorescein sodium for injection in angiography

14. Uncontrolled systemic hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 95 mmHg on optimal medical regimen)

15. Any previous systemic anti-VEGF treatment

16. Women of childbearing potential who are pregnant, planning to become pregnant, lactating, or not using adequate birth control, as specified in protocol. For women of childbearing potential, a serum pregnancy test must result negative at Screening.